PD-1 binding proteins and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10428145-B2
Application number	US-201615278425-A
Country	US
Kind code	B2
Filing date	Sep 28, 2016
Priority date	Sep 29, 2015
Publication date	Oct 1, 2019
Grant date	Oct 1, 2019

Abstract

Provided herein are compositions, methods and uses involving antibodies that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.

First claim

What is claimed:

1. An antibody or antigen-binding fragment thereof that binds to PD-1, wherein the antibody or antigen-binding fragment comprises:
a light chain variable region (VL) comprising:
a VL complementarity determining region 1 (CDR1) comprising SEQ ID NO:1,
a VL CDR2 comprising SEQ ID NO:2, and
a VL CDR3 comprising SEQ ID NO:3; and

a heavy chain variable region (VH) comprising:
a VH CDR1 comprising SEQ ID NO:4,
a VH CDR2 comprising SEQ ID NO:5, and
a VH CDR3 comprising SEQ ID NO:6.

2. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence of SEQ ID NO:8.

3. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence of SEQ ID NO:10.

4. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:11.

5. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:12.

6. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:13.

7. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:8; and
a VH comprising an amino acid sequence of SEQ ID NO:11.

8. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:8; and
a VH comprising an amino acid sequence of SEQ ID NO:12.

9. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:8; and
a VH comprising an amino acid sequence of SEQ ID NO:13.

10. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:10; and
a VH comprising an amino acid sequence of SEQ ID NO:11.

11. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:10; and
a VH comprising an amino acid sequence of SEQ ID NO:12.

12. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:10; and
a VH comprising an amino acid sequence of SEQ ID NO:13.

13. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

14. The antibody or antigen-binding fragment of claim 7 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

15. The antibody or antigen-binding fragment of claim 8 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

16. The antibody or antigen-binding fragment of claim 9 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

17. The antibody or antigen-binding fragment of claim 10 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

18. The antibody or antigen-binding fragment of claim 11 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

19. The antibody or antigen-binding fragment of claim 12 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

20. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

21. The antibody or antigen-binding fragment of claim 7 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

22. The antibody or antigen-binding fragment of claim 8 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

23. The antibody or antigen-binding fragment of claim 9 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

24. The antibody or antigen-binding fragment of claim 10 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

25. The antibody or antigen-binding fragment of claim 11 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

26. The antibody or antigen-binding fragment of claim 12 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

27. The antibody or antigen-binding fragment of 1 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

28. The antibody or antigen-binding fragment of 7 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

29. The antibody or antigen-binding fragment of 8 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

30. The antibody or antigen-binding fragment of 9 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

31. The antibody or antigen-binding fragment of 10 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

32. The antibody or antigen-binding fragment of 11 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

33. The antibody or antigen-binding fragment of 12 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

34. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

35. The antibody or antigen-binding fragment of claim 7 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

36. The antibody or antigen-binding fragment of claim 8 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

37. The antibody or antigen-binding fragment of claim 9 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

38. The antibody or antigen-binding fragment of claim 10 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

39. The antibody or antigen-binding fragment of claim 11 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

40. The antibody or antigen-binding fragment of claim 12 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

41. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antige

Assignees

• Celgene Corp

Inventors

• Bennett Brydon
• Chamberlain Philip Paul
• Hariharan Kandasamy
• Jackson Pilgrim
• Kehry Marilyn
• Khattri Roli
• Leung Monica
• Morrison Lisa
• Sun Jeonghoon
• Torres Sanaa
• Chan Henry H

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title